A groundbreaking study has revealed that a significant number of breast cancer patients may no longer require chemotherapy, thanks to a revolutionary DNA test. Conducted by researchers at University College London (UCL), the international trial suggests that over two-thirds of participants could effectively manage their condition with hormone therapy alone, thereby avoiding the often debilitating side effects associated with chemotherapy.
Key Findings from the Trial
The research, which involved more than 4,000 patients aged over 40 from the UK, Norway, Sweden, Australia, New Zealand, and Thailand, focused on the Prosigna gene test. This test assesses the activity of 50 genes related to breast cancer progression, allowing clinicians to evaluate the risk of cancer recurrence in individual patients. Those who received a low-risk score—accounting for approximately two-thirds of the cohort—were spared chemotherapy. Remarkably, the five-year survival rate for these patients stood at 93.7%, a figure that closely mirrors the 94.9% survival rate of those who underwent chemotherapy.
Traditionally, chemotherapy is administered post-surgery to reduce the risk of cancer returning, particularly in early-stage cases that have metastasised to adjacent lymph nodes. However, the findings from this study raise critical questions regarding the necessity of this treatment for patients with the most common breast cancer types. UCL estimates that around 5,000 patients within the NHS could avoid chemotherapy annually due to these findings.
Personal Stories Highlighting the Impact
Among those who participated in the trial is Karen Bonham from Cardiff, who expressed immense relief at the possibility of sidestepping chemotherapy. At 64 years old, Bonham underwent radiotherapy and hormone therapy for the past eight years, a choice made possible by the results of the Prosigna test. Her journey through cancer diagnosis, which she described as shocking and life-altering, underscores the emotional toll such a diagnosis can take. “Life priorities realign,” she noted, “you simply want to survive.”
The study’s findings will be presented at the upcoming American Society of Clinical Oncology (ASCO) annual meeting in Chicago, where it is expected to generate significant discussion among healthcare professionals. Professor David Miles, a leading figure in cancer research, characterised the results as “practice-changing.” He emphasised the potential to identify patients who derive no benefit from chemotherapy, thereby sparing them from unnecessary treatment and its associated hardships.
Reactions from the Cancer Community
The news has been met with enthusiasm from both patients and clinicians. Tanya Hutson, who received chemotherapy after her diagnosis in 2022, hailed the new test as “absolutely amazing.” She highlighted the stark contrast between her experience and that of patients who could avoid the “brutal” effects of chemotherapy, expressing hope that this advancement will change the landscape of breast cancer treatment.
While the results are promising, it remains uncertain whether the test’s efficacy extends to patients under 40. Further research is required before definitive conclusions can be drawn regarding this demographic.
Why it Matters
The implications of this study are profound. By potentially shifting treatment paradigms, the Prosigna test could significantly improve the quality of life for countless breast cancer patients, allowing them to avoid the often harsh realities of chemotherapy. As healthcare continues to evolve towards more personalised treatment approaches, this development not only underscores the importance of genetic research but also highlights the need for ongoing investment in cancer studies. The prospect of a tailored treatment plan that prioritises patient well-being is not just a medical breakthrough; it represents a fundamental shift in how society approaches cancer care.
